Zomedica — Third Quarter 2026 Earnings Summary

Zomedica Corp. reported record third-quarter revenue of $9.9 million for the period ended September 30, 2026, representing a 22% increase year-over-year. The company achieved a net loss of $3.2 million for the quarter, a 48% reduction from the prior year, while improving cash burn to $3.2 million. Diagnostic revenue surged 113% to $1.6 million, and the Therapeutic Devices segment contributed $7.2 million with a 64% gross margin. Total operating expenses decreased by 21% to $9.5 million, and the company ended the quarter with $40.9 million in liquidity.